Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 8/20 | 0.52 |
| ▸ | HTR2C | P28335 | 3/20 | 0.47 |
| ▸ | CTSS | P25774 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | DRD3 | P35462 | 3/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29404649 | 0.90 | HTR2C (0.47) | MTNR1BHTR2CCTSSALDH1A1DRD3 | |
| SCHEMBL28690252 | 0.90 | HTR2C (0.47) | MTNR1BHTR2CCTSSALDH1A1DRD3 | |
| SCHEMBL22411069 | 0.88 | MTNR1B (0.51) | MTNR1BHTR2CALDH1A1DRD3HTR1A | |
| SCHEMBL6405239 | 0.86 | MTNR1B (0.55) | MTNR1BHTR2CDRD3HTR1ACNR1 | |
| SCHEMBL2259511 | 0.84 | MTNR1B (0.53) | MTNR1BCNR1CNR2MTNR1A | |
| SCHEMBL2576042 | 0.81 | ABL1 (0.44) | MTNR1BHTR2CALDH1A1DRD3MTNR1A | |
| SCHEMBL2573895 | 0.81 | ABL1 (0.44) | MTNR1BHTR2CALDH1A1DRD3MTNR1A | |
| SCHEMBL2575580 | 0.81 | ABL1 (0.44) | MTNR1BHTR2CALDH1A1DRD3MTNR1A | |
| SCHEMBL6405341 | 0.81 | MTNR1B (0.50) | MTNR1BDRD3HTR1ATSHR | |
| Hydrochloric Acid SCHEMBL28064738 | 0.80 | ABL1 (0.44) | MTNR1BHTR2CALDH1A1DRD3MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288304-A1 | Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists | PFIZER INC | 2005-12-29 | — | — | US | claimed |
| WO-2005113527-A1 | TETRAHYDRONAPHTHYL- PIPERAZINES AS 5-HT1B ANTAGONISTS, INVERSE AGONISTS AND PARTIAL AGONISTS | PFIZER PRODUCTS INC. (US) | 2005-12-01 | — | — | WO | claimed |
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| US-20050288304-A1 | Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
| WO-2005113527-A1 | TETRAHYDRONAPHTHYL- PIPERAZINES AS 5-HT1B ANTAGONISTS, INVERSE AGONISTS AND PARTIAL AGONISTS | PFIZER PRODUCTS INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288304-A1 | Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists | HTR1A, HTR1B, HTR1D | MTNR1B 63/4885HTR2C 8/4885CTSS 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.